Cosmos Holdings Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2014; financial statements are unaudited. The filing identifies the registrant as Cosmos Holdings Inc. (the request metadata says Cosmos Health Inc.). Results compare the three and nine months ended September 30, 2014 with the corresponding 2013 periods.
Business context
Following its 2013 reverse takeover, the company operated through Cyprus subsidiary Amplerissimo and described itself as a holding company pursuing acquisitions and new business lines. The reported 2014 revenue came from services rendered during or before July 2013; management said Amplerissimo had not provided services on customer engagements after July 2013. A planned pharmaceutical wholesale business, SkyPharm, was seeking Greek regulatory licensing and lacked the capital to begin operations.
Key financial results
| Metric | Three months ended Sep. 30, 2014 | Nine months ended Sep. 30, 2014 | Prior-year comparable period |
|---|---|---|---|
| Revenue | $5,778,993 | $7,794,216 | $0 in both 2013 periods |
| Operating income | $5,586,255 | $7,360,044 | Losses of $79,341 and $573,060, respectively |
| Net income (loss) | $4,749,437 | $6,291,936 | Losses of $79,834 and $573,553, respectively |
| Net comprehensive income (loss) | $4,266,407 | $5,741,092 | Losses of $97,536 and $588,014, respectively |
| Basic and diluted EPS | $0.04 | $0.05 | Reported as approximately $0.00 loss and $0.01 loss, respectively |
| Operating cash flow | Not separately reported | $6,798,270 | $497,530 |
Direct consulting costs were $3,017 in each 2014 period, while general and administrative expenses were $189,721 for the quarter and $431,155 for nine months. The resulting high reported operating income reflects recognition of legacy service revenue with very low reported direct costs; the filing does not provide a meaningful conventional gross-margin discussion.
At September 30, cash was $84,425, accounts receivable $62,030, total assets $7,220,475, total current liabilities $1,525,662, and shareholders’ equity $5,694,813. Current liabilities included $1,099,965 of taxes payable, $179,092 of salaries payable, and a $165,000 related-party note. The company reported $63,520 of interest expense and $997,183 of income tax expense for the nine-month period. No cash interest or income taxes were reported as paid.
Material changes and unusual items
- Revenue and earnings rose sharply from 2013, when the comparable periods had no revenue and reported losses. The 2014 revenue was attributed to services rendered by July 2013 or earlier, not to ongoing customer engagements during 2014.
- Amplerissimo paid a $7,027,490 deposit toward a proposed €7 million acquisition of B2IN, which owns Greek pharmaceutical logistics subsidiary Unilog. The transaction remained subject to conditions outside Amplerissimo’s control; the filing says the deposit is refundable if closing does not occur. Management expected to fund the balance through debt or equity, with no assurance of obtaining financing on acceptable terms or at all.
- The nine-month cash-flow statement reports the $7,027,490 deposit as a financing cash outflow. Cash fell from $864,489 at year-end 2013 to $84,425 at September 30, 2014.
- Foreign currency translation losses were $483,030 for the quarter and $550,844 for nine months, reducing comprehensive income. The balance-sheet accumulated other comprehensive loss was $539,525.
- The company recognized a 12.5% Cyprus statutory tax rate on subsidiary earnings and maintained a full valuation allowance against U.S. deferred tax assets. It asserted that the foreign subsidiary investment was essentially permanent in duration and recorded no deferred tax liability on the outside-basis difference.
Liquidity, outlook, and risks
Management stated that cash and working capital would cover estimated operating cash needs for the next 12 months and estimated routine costs, including public-company reporting, at less than $300,000. However, MD&A states working capital was $5,694,813, the same amount as shareholders’ equity. Based on the balance sheet’s listed current assets (cash, receivables, prepaid expenses, and other assets) and current liabilities, working capital appears negative; the filing does not clearly reconcile this discrepancy.
Management planned to evaluate adding services and entering additional geographic markets, estimating $15,000 for each evaluation. It also planned to pursue pharmaceutical wholesale operations, contingent on licensing and financing. No binding customer engagements, expansion agreements, or acquisition commitments beyond the B2IN purchase agreement were described. The filing identifies risks including access to capital, competition, economic and regulatory changes, and the uncertainty of forward-looking plans. Management concluded disclosure controls were effective as of September 30, 2014; no material quarterly change in internal control was reported. No legal proceedings were disclosed.
Most important facts to verify
- Whether the reported legacy revenue recognition and collectability support are consistent with the underlying service records, given that services were rendered by July 2013 or earlier.
- The actual current-asset classification and working-capital position; reconcile MD&A’s stated $5.695 million of working capital with the balance sheet.
- The status and closing conditions of the B2IN acquisition, refund protections for the $7.027 million deposit, and committed financing for the remaining purchase price.
- The composition, payment timing, and tax treatment of the $1.100 million taxes payable, as well as the basis for the asserted indefinite duration of the foreign investment.
- The company’s ability to fund operations and launch SkyPharm, given cash of $84,425, unpaid salaries and related-party obligations, and the absence of post-July-2013 customer engagements.